Full CoverageTop coverage
Sage Therapeutics and Biogen Announce Positive Pivotal Phase 3 Results for Zuranolone, an Investigational Two-Week, Once-Daily Therapeutic Being Evaluated for Major Depressive Disorder
Biotech Stocks (NBI) Fall After Sage-Biogen (BIIB) Depression Drug Misses Mark
Sage antidepressant achieves goals of study, but questions linger
All coverage
Sage Therapeutics to Host Conference Call
Sage Stock Tumbles As Analysts Question 'Positive' Depression Drug Study
Biogen-Sage depression drug hits main goal of improving symptoms, then it gets complicated
Biogen Analyst Raises Price Target On Higher Chance Of Success For Depression Drug - Benzinga
Sage, Biogen's Zuranolone Meets Primary Endpoint in Phase 3 Trial
SAGE Stock Price Falls Over 10% Pre-Market: Why It Happened
Here's Why Sage Therapeutics Stock Is Sliding Today
Sage Therapeutics - Biogen's Zuranolone Tops Placebo In Reducing Depressive Symptoms
UPDATED: Sage's second chance at depression hits the PhIII primary, but questions remain over durability, side effects
Biogen, Sage's depression therapeutic zuranolone hits primary endpoint in phase 3
Premarket Movers Tuesday: Sage Therapeutics, MicroStrategy
Sage's Depression Drug Worked. Here's Why the Stock Is Falling.
While Sage Therapeutics sees a window for depression drug, market is skeptical
Sage, Biogen MDD treatment meets primary endpoint
Sage depressed by Waterfall | Evaluate
Sage Therapeutics Plunges After Depression Drug-Trial Results
Pivotal Late-Stage Trial Shows Major Depressive Drug Significantly Reduces Symptoms
Sage's depression drug study results show improvement in symptoms
Short-Course Zuranolone Looks Promising for MDD Treatment
UPDATE 2-Sage's depression drug study results show improvement in symptoms
